Fig. 4: FUT2 suppresses the ferroptosis of CRC cells.

A SW480 and DLD-1 cells were transfected with FUT2-shRNA, and then the ROS level was assessed by flow cytometry. The bar graph showing ROS level was expressed as a percentage of the control. Data shown are mean ± SD; n = 3 samples. B, C SW480 cells were transfected with FUT2-shRNA, and then the levels of MDA, GSH and glutathione disulfide (GSSG) levels were assessed. Data shown are mean ± SD; n = 3 samples. D SW480 cells were transfected with FUT2-shRNA, and then western blot analysis of key ferroptosis markers, including GPX4, FTH, and TFR1 expressions were determined. The relative density of protein bands was quantified, normalized to α-tubulin, and fold changes were shown in histograms from three independent experiments. SW480 cells were transiently transfected with FUT2-shRNA (E) or FUT2/Lv105 (F). After transfection, the cells pre-treated with RSL3 (2 μM) were treated with ferrostatin (Fer-1) (1 μM) for 24 h, and then the level of MDA was determined. Data shown are mean ± SD; n = 3 samples. G Cell viability assay in SW480 cells treated with indicated concentrations of cisplatin for 24 h, showing that FUT2 expression modulates cisplatin sensitivity. Data shown are mean ± SD; n = 3 samples. Statistical significance was determined using one-way ANOVA using the Bonferroni post-hoc test, with *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns: not significant.